A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial

Trial Profile

A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary) ; Topotecan (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Acronyms BEACON; BEACON-Neuroblastoma Trial
  • Most Recent Events

    • 05 May 2017 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
    • 05 May 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
    • 28 Oct 2016 Planned number of patients changed from 120 to 160.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top